Paula Newton speaks with co-founder and Chair of Moderna, Noubar Afeyan, about his hopes for the release of Ruben Vardanyan, ...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

One of the most underappreciated applications of artificial intelligence in the corporate world involves its role in writing ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...